OP-211 : Trends in Statin Consumption and Cardiovascular Mortality in Croatia 2004 – 2012

Author(s): 
Zeljko Vojvodic1, Mladenka Vrcic Keglevic2 1Zeljko Vojvodic, Family Practice "Dr Zeljko Vojvodic" Bijelo Brdo, Osijek, Croatia and Foundation for the Development of Family Medicine in Croatia, Zagreb, Croatia 2Mladenka Vrcic Keglevic, University of Zagreb Medical School, School of Public Health "Andrija Stampar", Zagreb and Foundation for the Development of Family Medicine in Croatia, Zagreb, Croatia
Text: 
Background and aims Prescribing of statins increased in all developed countries since 1995, growing at faster rates than other ATC groups. That rise was regarded desirable and benefitial, because of their unquestionable efficiency in controlling atherogenic dyslipidaemia. The aim was to research trends in statin therapeutic and financial consumption in the period from 2004 to 2012 as well as trends in cardiovascular mortality from 1980 to 2012. Methods Longitudinal, observational study, based on data on the use of statins, from Croatian Agency for Medicinal Products and Medical Devices, from 2004 – 2012, together with financial expenses (in EUR). Data on cardiovascular mortality in Croatia and several neighbouring countries were taken from the Croatian Health Statistics Yearbooks. Results Pharmaceutical consumption of statins increased from 28,1 DDD/TID in 2004 to 83.5 DDD/TID in 2012 (near 200%). The most frequently prescribed simvastatin and atorvastatin, rised at different rates - simvastatin 64%, atorvastatin 440% - from 8.8 DDD/TID in 2004 to 47.9 DDD/TID in 2010, with 50% drop in utilization rate in 2011 due to doubling of DDD for the C10 group. Financial expenses for statins expanded at a rate of 53%, from 21.3 millions of EUR in 2004 to 32.4 millions of EUR in 2012. Their share in total drug expenses grew up from 4.25% to 4.87% in 2012. As opposed to that, trends in standardized cardiovascular mortality, as well as mortality rates from ischaemic heart disease and cerebrovascular disease continually declined in Croatia (and several neighbouring countries) since 1980s – from 551,65/100.000 to 351/100.000. Conclusions Utilization of statins in Croatia increased more than in any other therapeutic group, in the eight year period, while standardized cardiovascular mortality rates decreased in balanced linear mode.
Keywords: statin consumption, cardiovascular mortality, pharmaceutical spending